Coming October 29: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

Earle A. Chiles Research Institute, Providence Cancer Institute at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Earle A. Chiles Research Institute, Providence Cancer Institute brings 6 presentations to SITC 2026 in Phoenix. Its program centres on finding markers of who responds to immunotherapy, often by imaging many proteins at once on tissue, and on T cells that recognize tumors. One concrete item reports a head and neck cancer trial pairing pembrolizumab before surgery with targeted radiation that spares the lymphatic system.

Organization	SITC 2026 Attendance
EA Earle A. Chiles Research Institute, Providence Cancer Institute Portland, OR
Cancer centres & hospitals A cancer research institute within Providence Cancer Institute, conducting translational and clinical cancer research.	Poster Fri Nov 6 12:15–1:45pm 5:30–7pm T regulatory cells as a mechanistic driver and predictive biomarker of response to aPD-1+aLAG-3 therapy Exhibition Halls 4-6 · Poster 467 Biomarkers · Tumor biology Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm Harnessing Circulating Early-Memory Tumor-Reactive T cells for Adoptive Cell Therapy of Gastrointestinal Tumors Exhibition Halls 4-6 · Poster 282 Cell therapy Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm Multi-omics analysis revealed elevated tumor-reactive T cells and KIR3DL1+ mature NK cells in responders to high-dose interleukin-2 therapy Exhibition Halls 4-6 · Poster 122 New agents · Biomarkers Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm Same-slide proximity ligation and multiplex immunofluorescence uncovers cell-type-specific PD-1/PD-L1 checkpoint dynamics in melanoma sentinel lymph nodes Exhibition Halls 4-6 · Poster 140 Models & tech · Biomarkers Talk Sat Nov 7 12:30pm–12:38pm Part of Session 204a: Rapid Oral - Basic 2 Single-Assay Mapping of Antibody Drug Conjugate Target Co-expression and Immune Contexture in Pan-Cancer Tissue Microarrays with Multiplex Immunofluorescence 301A Biomarkers · Models & tech Talk Sat Nov 7 4:30pm–4:37pm Part of Session 206d: Novel Paradigms for Effectively Combining Immunotherapies with Radiopharmaceuticals or Radiation Therapy Lymphatic‑sparing neoadjuvant SABR and pembrolizumab (Neo-ImmunoSABR) in HPV‑negative HNSCC: results from a phase II multi-center trial with immune correlates 301BC Clinical

Organization

SITC 2026 Attendance

Earle A. Chiles Research Institute, Providence Cancer Institute

Portland, OR

Cancer centres & hospitals

A cancer research institute within Providence Cancer Institute, conducting translational and clinical cancer research.

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

T regulatory cells as a mechanistic driver and predictive biomarker of response to aPD-1+aLAG-3 therapy

Exhibition Halls 4-6 · Poster 467

Biomarkers · Tumor biology

Poster